12:00 AM
Dec 09, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Xtandi enzalutamide: Phase II started

Medivation and partner Astellas began a double-blind Phase II trial to compare Xtandi plus exemestane vs. placebo plus exemestane in 240 postmenopausal women with breast cancer that is estrogen receptor- or progesterone receptor-positive and normal for HER2 and who have received...

Read the full 192 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >